KOFA Healthcare is an evergreen family office venture fund supporting biotech and healthcare innovations. We actively invest in groundbreaking technologies that address clinical unmet needs.
We invest in women’s health, orthopedics, diagnostics, cardiovascular, and more. Our previous successful investment stories range from seed stage startups to commercial stage corporations.
Our Healthcare Portfolio
Venova is developing the Velocity System, a next generation percutaneous AVF technology designed to reduce the need for reinterventions to achieve fistula maturation and improve vascular access outcomes while reducing costs.
CorFlow is developing a medical device that will be the first to diagnose MVO in real-time during PCI and serve as a treatment platform in the cath lab.
Aria’s device is designed to treat a form of PH called World Health Organization (WHO) Group 1 PH, also known as Pulmonary Arterial Hypertension (PAH).
Axena Health is a women-led company dedicated to improving the lives of women with pelvic floor disorders and is unapologetically focused on helping them live their best lives by harnessing the power of digital technology. Axena’s Leva® Pelvic Health System helps women train and strengthen their pelvic floor muscles—at home, in just five minutes a day—to treat their stress, mixed and mild-to-moderate-urgency urinary incontinence (including overactive bladder) and chronic fecal incontinence.
We are working relentlessly to democratize blood pressure management at global scale using breakthrough transdermal optical biosensing in mobile devices.
EyeArt is the first FDA cleared AI technology for autonomous detection of both more than mild and vision-threatening diabetic retinopathy. The EyeArt® AI Eye Screening System is the most extensively validated autonomous AI technology, tested on over half a million patient visits globally with over two million images collected in real-world clinical environments.
In developing Lumerah™, a noninvasive sensor technology that directly measures fetal oxygen levels, Raydiant Oximetry aims to profoundly reduce the rising mortality and morbidity rates among mothers and babies during childbirth.
CareTaker has developed the VitalStream monitoring system that sets a new standard in portability, simplicity, and medical-grade wearable wireless vital signs monitoring. VitalStream uses a small, comfortable finger cuff to accurately measure continuous, non-invasive beat-by-beat Blood Pressure (“cNIBP”), ECG-Accurate Heart Rate, and Respiration Rate. It can also be used to monitor Blood Volume (for hemorrhage detection), Arterial Stiffness, and other hemodynamic parameters.
Nectero Medical is developing a novel treatment to stabilize growth and prevent rupture of mid-sized abdominal aortic aneurysms (AAA). The Nectero EAST®, or Endovascular Aneurysm Stabilization Treatment System, delivers a compound with a proprietary molecule known as a Stabilizer Agent to the site of the aneurysm.
Acquired by Organon. Alydia Health is a commercial-stage medical device company focused on preventing maternal morbidity and mortality caused by postpartum hemorrhage (PPH) or abnormal postpartum uterine bleeding.
RIVANNA develops and commercializes world-first, imaging-based medical technologies. Our automated clinician-assistance solutions help improve decision-making, clinician workflows, health outcomes, and patient satisfaction.
Cerapedics is a global, commercial-stage ortho-biologics company that aspires to transform the standard of care for bone repair, healing bones faster and at higher rates, without compromising safety, so that patients can live their healthiest lives.